For the second quarter of the fiscal year ending March 2027, consolidated net sales were 15,821 million yen, operating loss was 6,960 million yen, and interim net loss attributable to owners of parent was 512 million yen. Compared with the same period in fiscal 2026, net sales were -0.7% YoY and operating profit turned negative. Full-year forecast remains unchanged from the previous announcement. Cash and cash equivalents decreased to approximately 4,276 million yen. Profitability was pressured by new product launches and higher costs.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4539","jir_company_name":"Nippon Chemiphar Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4539-20261030-01.pdf","jir_short_summary":"For the second quarter of the fiscal year ending March 2027, consolidated net sales were 15,821 million yen, operating loss was 6,960 million yen, and interim net loss attributable to owners of parent was 512 million yen. Compared with the same period in fiscal 2026, net sales were -0.7% YoY and operating profit turned negative. Full-year forecast remains unchanged from the previous announcement. Cash and cash equivalents decreased to approximately 4,276 million yen. Profitability was pressured by new product launches and higher costs.","jir_summary":"### Overview of Results\nFor the second quarter of the fiscal year ending March 2027, consolidated net sales were 15,821 million yen, showing almost flat movement year-on-year, while operating loss widened to 6,960 million yen, turning to a deficit. Ordinary income was -684 million yen, and interim net loss attributable to owners of parent expanded to 512 million yen. While sales were maintained mainly in the pharmaceuticals segment, cost increases from yen depreciation and higher R&D expenses for new products and drugs pressured profits. Although the full-year forecast remains unchanged, cash balances have declined.\n\n### Outlook and Impact on Shareholders\nThe full-year performance forecast has not been revised from the previously announced outlook; however, the substantial interim deficit suggests room for financial improvement. Given the potential continuation of reduced cash holdings and rising raw material costs, reviewing cost structure and the pace of new product market introductions will be key. There is no information disclosed regarding direct dividend forecasts for shareholders.","jir_financial_highlights":"Net Sales: 15,821 (YoY -0.7%)\nOperating Income: -696 (Prior-year period 122)\nOrdinary Income: -684 (Prior-year period 48)\nInterim Net Loss Attributable to Owners of Parent: -512 (Prior-year period 163)\nNet Loss per Share: -141.57 (Prior-year period 45.27)\nTotal Assets: 48,801 (-1,177)\nEquity Ratio: 38.7% (Prior fiscal period 39.0%)\nCash and Cash Equivalents at End of Period: 4,276 (-long-term comparison)","jir_category":"","jir_hashtags":"#NipponChemiphar, #Earnings, #InterimResults","jir_key_figures":"Net Sales: 15,821 million yen (YoY -0.7%)\nOperating Loss: -696 million yen (Prior-year period: operating income 122 million yen)\nInterim Net Loss: -512 million yen (Prior-year period: net income 163 million yen)","jir_meta_title":"Nippon Chemiphar Co., Ltd. Financial Summary for Q2 FY2027 | Net Sales 15,821 million yen, Operating Loss Widens","jir_meta_description":"Financial summary for Nippon Chemiphar Co., Ltd. Q2 FY2027: net sales of 15,821 million yen, operating loss of 6,960 million yen, net loss of 512 million yen. Pharmaceuticals is the primary segment. Full-year forecast unchanged. Cash balances decreasing.","jir_og_title":"Nippon Chemiphar Co., Ltd. | Financial Summary for Q2 FY2027","jir_og_description":"In Q2, Nippon Chemiphar reported net sales of 15,821 million yen, an operating loss of 6,960 million yen, and a net loss of 512 million yen, turning to a deficit. Full-year forecast remains unchanged.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":59491,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138893","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n